Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CSL TIV (Afluria) in Children 5-9 Years
NCT02212106Phase 4Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of standard dose influenza vaccine in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoint: The Frequency and Intensity of Fever Events Occurring During the 7 Days After Each Administration of CSL TIV Vaccine. Started Sep 2014; status: completed.
02
Drugs
standard dose influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02212106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212106.